Bristol Myers Squibb Q1 2025 Update
Ticker: CELG-RI · Form: 10-Q · Filed: Apr 24, 2025 · CIK: 14272
| Field | Detail |
|---|---|
| Company | Bristol Myers Squibb Co (CELG-RI) |
| Form Type | 10-Q |
| Filed Date | Apr 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials, debt
TL;DR
BMS Q1 2025: Sales and revenue figures released, with details on notes and CVRs.
AI Summary
Bristol Myers Squibb Co. reported its first quarter 2025 results, ending March 31, 2025. The company's filing details various financial components, including net product sales and alliance and other revenues for the first quarters of 2025 and 2024. It also references specific debt instruments like the A1.000% Notes due 2025 and A1.750% Notes due 2035, as well as Celgene Contingent Value Rights.
Why It Matters
This filing provides investors with a snapshot of Bristol Myers Squibb's financial performance and debt obligations for the first quarter of 2025, crucial for understanding the company's current financial health.
Risk Assessment
Risk Level: medium — The filing mentions a 'lawsuit' and 'Celgene ContingentValueRights', which could indicate potential financial liabilities or complexities.
Key Numbers
- 2025-01-01 to 2025-03-31 — Q1 2025 Period (Reporting period for current quarter financial data.)
- 2024-01-01 to 2024-03-31 — Q1 2024 Period (Reporting period for prior year comparable quarter financial data.)
- 2025-03-31 — As of Date (Date for balance sheet information.)
- 2024-12-31 — Prior Year End (Date for prior year-end balance sheet information.)
Key Players & Entities
- BRISTOL MYERS SQUIBB CO (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250424 (date) — Filing Date
- A1.000% Notes due 2025 (dollar_amount) — Debt Instrument
- A1.750% Notes due 2035 (dollar_amount) — Debt Instrument
- Celgene ContingentValueRights (company) — Financial Instrument
- lawsuit (other) — Legal Matter
FAQ
What were Bristol Myers Squibb's Net Product Sales for Q1 2025?
The filing indicates Net Product Sales for the period January 1, 2025 to March 31, 2025.
How do Q1 2025 Alliance and Other Revenues compare to Q1 2024?
The filing provides Alliance and Other Revenues for both January 1, 2025 to March 31, 2025 and January 1, 2024 to March 31, 2024.
What is the par value of Bristol Myers Squibb's common stock?
The filing specifies Bristol Myers Squibb's common stock has a par value of $0.10.
Does the company have any upcoming debt maturities in 2025?
Yes, the filing references 'A1.000% Notes due 2025'.
Are there any contingent value rights mentioned in the filing?
Yes, the filing mentions 'Celgene ContingentValueRights'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on April 24, 2025 regarding BRISTOL MYERS SQUIBB CO (CELG-RI).